v3.26.1
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY - Veraxa Biotech A G [Member] - CHF (SFr)
Subscribed Capital [Member]
Capital Reserves [Member]
O C I [Member]
Retained Earning [Member]
Total Equity [Member]
Balance, June 25, 2025 (inception) at Dec. 31, 2023 SFr 13,409,213 SFr 44,960,451 SFr 489,459 SFr (3,731,379) SFr 55,127,744
IfrsStatementLineItems [Line Items]          
Loss for the period (28,132,971) (28,132,971)
Other result - currency conversion (711,962) (711,962)
Share based compensation in relation to ESOP 2,930,321 2,930,321
Proceeds from the issuance of share capital 244,433 2,398,325 2,642,758
Cost of share issuance (801,074) (801,074)
Share capital issued in connection with acquisitions 528,543 (528,543)
Ending balance, value at Dec. 31, 2024 14,182,189 48,959,480 (222,503) (31,864,350) 31,054,816
IfrsStatementLineItems [Line Items]          
Loss for the period (66,613,990) (66,613,990)
Other result - currency conversion (69,022) (69,022)
Share based compensation in relation to ESOP 14,106,551 14,106,551
Proceeds from the issuance of share capital 568,878 6,288,524 6,857,402
Cost of share issuance (1,101,904) (1,101,904)
Ending balance, value at Dec. 31, 2025 14,751,067 68,252,651 (291,525) (98,478,340) (15,766,147)
Ending balance, value at Dec. 31, 2025 SFr 14,751,067 SFr 68,252,651 SFr (291,525) SFr (98,478,340) SFr (15,766,147)